Investor Relations





         Nasdaq: PRPH

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Company Overview

ProPhase Labs Inc. (OTC Pink Limited: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.

Investor Contact Information

Company

ProPhase Labs, Inc.
626 RXR Plaza, 6th Floor
Uniondale, NY 11556

Investor Relations

Investor Relations Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
T: 1-800-REDCHIP (733-2447), 1-407-644-4256
PRPH@redchip.com

Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
T: (416) 644-2020 or (212) 812-7680
jboidman@renmarkfinancial.com
https://www.renmarkfinancial.com/